Aadi Bioscience, Inc.
NASDAQ Capital MarketTotal Valuation
Aadi Bioscience, Inc. carries a market capitalization of 94.89M, placing it among publicly traded companies globally. Its enterprise value stands at -177.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 94.89M |
| Enterprise Value | -177.32M |
Share Statistics
Aadi Bioscience, Inc. currently has 46.78M shares outstanding.
| Shares Outstanding | 46.78M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Aadi Bioscience, Inc. trades at a trailing price-to-earnings ratio of 1.95. The price-to-sales ratio is 1.94, and the price-to-book ratio stands at -0.21.
| PE Ratio | 1.95 |
| PS Ratio | 1.94 |
| PB Ratio | -0.21 |
| P/TBV Ratio | 0.24 |
| P/FCF Ratio | -1.07 |
| P/OCF Ratio | -1.04 |
Enterprise Valuation
| EV / Sales | 1.51 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Aadi Bioscience, Inc. maintains a current ratio of 18.95, meaning it holds 18.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 18.95 |
| Quick Ratio | 18.83 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -628.40 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 16.00 |
| Return on Invested Capital (ROIC) | -38.63 |
| Return on Capital Employed (ROCE) | -10.16 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.06 |
Stock Price Statistics
Aadi Bioscience, Inc.'s stock has gained approximately 12.63736% over the past 52 weeks. The 50-day moving average sits at 2.56, while the 200-day moving average is 2.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | 12.63736% |
| 50-Day Moving Average | 2.56 |
| 200-Day Moving Average | 2.16 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Aadi Bioscience, Inc. generated 27.78M in revenue and converted that into 27.61M in net income, yielding earnings per share of 0.91. EBITDA reached -60.33M, while operating income came in at -60.53M.
| Revenue | 27.78M |
| Gross Profit | 24.64M |
| Operating Income | -60.53M |
| Pretax Income | 27.61M |
| Net Income | 27.61M |
| EBITDA | -60.33M |
| EBIT | -60.53M |
| Earnings Per Share (EPS) | 0.91 |
Balance Sheet
Total book value stands at -259.63M, with working capital of 220.34M providing operational flexibility.
| Cash & Cash Equivalents | 231.06M |
| Total Debt | N/A |
| Net Debt | -227.57M |
| Equity (Book Value) | -259.63M |
| Book Value Per Share | -8.60 |
| Working Capital | 220.34M |
Cash Flow
Aadi Bioscience, Inc. produced -51.76M in operating cash flow over the past twelve months. After subtracting -1.47M in capital expenditures, free cash flow totaled -53.23M - equivalent to -1.76 per share.
| Operating Cash Flow | -51.76M |
| Capital Expenditures | -1.47M |
| Free Cash Flow | -53.23M |
| FCF Per Share | -1.76 |
Margins
Aadi Bioscience, Inc. operates with a gross margin of 88.72, reflecting its pricing power and cost economics. The operating margin of -217.92 and net profit margin of 99.42 provide insight into operational efficiency.
| Gross Margin | 88.72 |
| Operating Margin | -217.92 |
| Pretax Margin | 99.42 |
| Profit Margin | 99.42 |
| EBITDA Margin | -217.20 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -177.39 |
| FCF Yield | -93.35 |
Stock Splits
Aadi Bioscience, Inc.'s most recent stock split took place on August 27, 2021 with a 15:1 split ratio.
| Last Split Date | 8/27/2021 |
| Split Ratio | 15:1 |
Scores
Aadi Bioscience, Inc. posts an Altman Z-Score of 1.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.47 |